PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2072672
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2072672
According to Mordor Intelligence, the u.S. cord blood banking services market size is projected to be USD 9.94 billion in 2025, USD 10.09 billion in 2026, and reach USD 19.15 billion by 2031, growing at a CAGR of 11.55% from 2026 to 2031.

This report is Segmented by Bank Type (Private, Public), Service Type (Collection & Logistics, Processing & Testing, Cryo Storage, Retrieval & Release), Stored Material (Cord Blood, Cord Tissue, Placental Tissue), Application (Cancers, Blood Disorders, Metabolic Disorders, Others), End Use (Hospitals, Transplant Centers, Research Institutes, Home Storage), & Geography (US). Forecasts in Value (USD).
Awareness of newborn stem cell preservation varies significantly across racial, linguistic, and income demographics, indicating that demand is closely tied to education and trust-building efforts. A 2025 study highlighted that only 31.4% of Spanish-speaking pregnant Hispanic women were aware of cord blood banking, with 70% lacking understanding of its purpose. The study also noted that 91.3% of respondents cited lack of knowledge as a barrier, 63% expressed distrust, and 20% had fears about donation. This highlights the importance of targeted outreach in driving enrollment growth. Hispanic families, a significant and growing birth cohort in the United States, remain underrepresented, leading to reduced supply despite high demand.
Cord blood is increasingly being utilized for a broader range of hematologic and immune disorders, moving beyond its traditional focus on leukemia. The C.W. Bill Young Cell Transplantation Program facilitated over 8,400 unrelated hematopoietic cell transplants in fiscal year 2025, demonstrating the scale of unrelated donor transplantation in the United States. In April 2026, the FDA approved Cellenkos for a Phase 2 trial of CK0801, a cord blood-derived therapy targeting transfusion-dependent aplastic anemia patients. Phase 1 results from 2024 showed promising outcomes, with a significant percentage of patients achieving health milestones.] Additionally, Fred Hutch reported a 96% one-year survival rate in April 2026 for patients using a pooled cord blood transplant, with no severe graft versus host disease cases observed. These developments reinforce the growing role of cord blood in transplants and emerging therapies.
In the United States, high private banking costs significantly limit family enrollment in cord blood banking services. Consumers face charges between USD 1,500 and USD 3,000 for collection and processing, with annual storage fees ranging from USD 150 to USD 300. Over 20 years, total costs can exceed USD 4,000 for cord blood storage alone and USD 8,000 for combined cord blood and tissue storage. These expenses disproportionately affect lower-income households and families who could benefit from diverse inventories. Simplifying payment structures, clarifying benefits, and emphasizing HSA or FSA eligibility can help private banks reduce enrollment drop-offs.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
In 2025, private banking held 56.35% of the United States cord blood banking services market share, driven by an accumulated enrolled base rather than clinical superiority over public banking. Private banks benefit from subscription-based storage, strong consumer branding, and monetization of collection, processing, and long-term storage through family relationships.
Public banking is projected to grow at an 11.95% CAGR through 2031, making it the faster-growing segment in the United States cord blood banking market. Growth is driven by HRSA contract renewals, transplant center reliance on public inventory, and demand for genetically diverse units. Regulatory requirements, including FDA and state-level licensing, favor hybrid operators managing both family storage and public programs, enabling them to optimize margins while serving diverse channels.
Cryogenic storage and monitoring accounted for 66.76% of the United States cord blood banking services market in 2025, reflecting the long-term fee model sustaining private banking. Storage generates recurring revenue, funds laboratory operations, and supports cross-selling of related services. Efficient collection and logistics remain critical, though the focus is shifting toward services enhancing quality and usability.
Processing and testing is expected to grow at a 12.25% CAGR through 2031, driven by demand for validated cell recovery, viability, and release readiness. Platforms like Cryo-Cell International's PrepaCyte-CB emphasize improved cell recovery, while retrieval and release services are set to rise with increased transplant use and investigational programs. This shift enhances revenue per stored unit and prioritizes laboratory capabilities over storage capacity.